With a market cap of $159.9 billion, Gilead Sciences, Inc. (GILD) is a global biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs across areas such as HIV, liver diseases, cancer, and infectious diseases. It offers a broad portfolio of treatments and collaborates with multiple organizations to advance innovative therapies worldwide. Shares of the Foster City, California-based company have underperformed the broader market over the past 52 weeks. ...